Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Sales, Conference Call, Webcast, Advisory

NICE Provides Dial-in Details for its First Quarter 2024 Results Teleconference


NICE (Nasdaq: NICE) will announce its first quarter 2024 results on Thursday, May 16, 2024, before the opening of the NASDAQ Stock Exchange.
Later that day, management will host a conference call to discuss the results.

8:30 AM - Eastern
1:30 PM - UK
3:30 PM - Israel

To participate, please call one of the dial-in numbers approximately 15 minutes before the start time:

US: +1-877-407-4018 (toll free) or +1-201-689-8471
Israel: +1-809-406-247 (toll free)
UK: +0-800-756-3429 (toll free)

When prompted please give your name and company.
If you need assistance during the conference, press * then 0 on your telephone and a conference coordinator will be happy to assist you.

The call will be webcast live on the Company's website at https://www.nice.com/company/investors/upcoming-event.

Kind Regards,
NICE Investor Relations

About NICE

NICE (Nasdaq: NICE) is the world's leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.


These press releases may also interest you

at 02:46
OKX, a leading Web3 technology company, has issued updates for May 20, 2024. OKX DEX Incorporates ChangeNOW's Cross-Chain Bridges:...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
Astera Labs , a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced expanded PCIe® 6.x testing capabilities in its Cloud-Scale Interop Lab to enable seamless interoperability between Aries 6...

at 02:05
Exchange Solutions, a leading provider of personalized loyalty solutions, proudly announces the launch of groundbreaking Generative AI features integrated into its loyalty platform. This innovative advancement, now available for use within the SaaS...



News published on and distributed by: